Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: J Immunol. 2016 Mar 2;196(7):3079–3087. doi: 10.4049/jimmunol.1502061

Fig. 6. Reconstitution of HBs-specific cytotoxic T cells by combination treatment with NAb and EnxB plus TLR9 agonistics.

Fig. 6

(A) The time course of combination treatment with NAb and EnxB (1 µg), plus CpG (50 µg) administered to HBV carrier mice. (B) Mice were sacrificed on day 16 post first immunization. Intra-hepatic HBs-specific CTLs were monitored by ELISPOT assays after stimulation with ENV190–197 or control peptide OVA257–264. (C) Serum level of ALT (sALT) on 7 days post the last vaccination from (n=5). (D) Serum levels of HBs (left), HBeAg (middle), and HBV genomic DNA (right) were evaluated on day 0 (starting NAb treatment), week 5 (starting vaccine treatment), and week 12 (6 weeks after 2nd vaccination) respectively. (E) Intra-hepatic capsid-associated HBV genomic DNA (left), HBs (middle), and HBeAg (right) were monitored on the day when the experiment was terminated and mice were sacrificed (n=3). The data presented are representative of three independent experiments (mean± SD).